MWM
NMRA icon

Meridian Wealth Management’s Neumora Therapeutics NMRA Stock Holding History

Meridian Wealth Management’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$200K Buy
102,400
+16,000
+19% +$41.5K 0.01% 752
2025
Q4 		$155K Buy
86,400
+27,000
+45% +$59.1K 0.01% 733
2025
Q3 		$108K Buy
+59,400
New +$96K ﹤0.01% 693

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return

Meridian Wealth Management's NMRA Position: Q1 2026 in Review

Meridian Wealth Management increased its Neumora Therapeutics (NMRA) stake by 19% in Q1 2026, buying an estimated $41.5K and bringing the position to 102,400 shares worth $200K. The position accounts for 0.01% of the portfolio, ranked #752.

Meridian Wealth Management first reported a position in NMRA in Q3 2025 and has held it in 3 quarters since. 114 funds tracked by Wall St. Rank hold NMRA as of Q1 2026.

  • Meridian Wealth Management held 102,400 shares of Neumora Therapeutics worth $200K as of Q1 2026.
  • Meridian Wealth Management bought 16,000 Neumora Therapeutics shares in Q1 2026, an estimated $41.5K.
  • Neumora Therapeutics made up 0.01% of Meridian Wealth Management's portfolio in Q1 2026, its #752 holding.
  • Meridian Wealth Management first reported a position in Neumora Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 114 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2026.

Based on Meridian Wealth Management's 13F filing for Q1 2026, filed 6 May 2026.